On Dec. 19, 2023, LNC received the IND approval from the NMPA for the 18F-LNC1005 Injection, and will enter the clinical trial soon.

18F-LNC1005 Injection is a FAP-targeted radionuclide diagnostic drug, registered as Class 1 chemical drugs. Suitable for positron emission tomography (PET) imaging of FAP-positive solid tumor patients. The targeting specificity of FAP enables the delivery of radionuclide fluoride [18F] to the lesion sites of FAP-positive solid tumors, by using PET imaging to achieve the diagnostic purpose.

At present, there is no therapeutic or diagnostic drug with the same target on the market or under development in China, and there is no similar product on the market worldwide, which may fill the gap in the market. This is the 2nd radionuclide drug approved for clinical trial globally since LNC was established.